REVIEW article
Front. Endocrinol.
Sec. Diabetes: Molecular Mechanisms
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1638770
This article is part of the Research TopicInflammatory biomarkers in Type 1 diabetesView all 4 articles
Cardiovascular risk factors and modern therapeutic strategies in children and adolescents with type 1 diabetes to prevent future diabetic angiopathy in the era of innovative miRNAs biomarkers
Provisionally accepted
Joanna Peczyńska
Emilia OdyjewskaKamila Koszykowska
Milena Jamiołkowska-Sztabkowska
Artur Bossowski
Barbara Glowinska-Olszewska*- Medical University of Bialystok, Bialystok, Poland
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Type 1 diabetes (T1D) in children is a serious, chronic, incurable disease associated with the frequent and early occurrence of additional, well-known cardiovascular risk factors and exacerbation of the risk of future cardiovascular diseases (CVD). Lately, accumulating evidence suggests that exosomal miRNAs play a major role not only in the pathophysiology of T1D but also in its late complications. Since premature CVD is one of the leading causes of morbidity and mortality in diabetes, considerable efforts have been made to define the molecular and pathological features and to develop new diagnostic and therapeutic strategies. Dysregulation of the expression or function of various miRNAs may affect angiogenesis, vascular inflammation, or cardiac remodeling, which play key roles in the development and progression of cardiovascular complications. While CVD usually appear in adulthood, pathology and early markers may appear during adolescence, emphasizing the need for careful monitoring and prevention in this age group. In this narrative review, we aimed to summarize the latest findings on miRNAs and their role as biomarkers of cardiovascular risk factors and subsequent complications in children with T1D, presenting promising candidates for clinical applications.
Keywords: type 1 diabetes, Children, cardiovascular risk factors, cardiovascular complications, miRNA, precise medicine
Received: 31 May 2025; Accepted: 18 Aug 2025.
Copyright: © 2025 Peczyńska, Odyjewska, Koszykowska, Jamiołkowska-Sztabkowska, Bossowski and Glowinska-Olszewska. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Barbara Glowinska-Olszewska, Medical University of Bialystok, Bialystok, Poland
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.